Crossmark

Efficacy and safety of a particulate yeast β-glucan preparation in the treatment of seasonal allergic rhinitis (BETALL): a randomised placebo-controlled crossover trial protocol

Crossref DOI link: https://doi.org/10.1186/s13063-026-09702-7

Published Online: 2026-04-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Briskey, David

Pellow, Janice

Beatson, Gemma

Tremblay, Annie

Rao, Amanda

Tompkins, Thomas A.
License Information

Text and Data Mining valid from 2026-04-17

Version of Record valid from 2026-05-28
More Information

Article History

Received: 23 July 2025

Accepted: 2 April 2026

First Online: 17 April 2026

Declarations

:

: This trial was approved by the Belberry Human Research and Ethics Committee, Protocol Number 202502222 on 2nd April 2025. All study activities will be conducted in accordance with the Declaration of Helsinki, and all participants will provide written informed consent. This trial was registered at ClinicalTrials.gov (NCT06907680).

: Not applicable.

: TAT and AT are employed by Lallemand Bio-Ingredients. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below